Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	1.74	1.63	0.48	1.76
Research & Development	0.25	0.08	0.09	0.18
Operating Expenses	1.99	1.71	0.57	1.94
Operating Income	-1.99	-1.71	-0.57	-1.94
Interest Expense	-0.76	-0.1	-0.46	-0.16
Other Non Operating Income (Expenses)	-	-	-0.02	-0.04
Pretax Income	-2.74	-1.81	-1.05	-2.15
Net Income	-2.74	-1.81	-1.05	-2.15
Net Income to Common	-2.74	-1.81	-1.05	-2.15
Shares Outstanding (Basic)	11	10	10	9
Shares Outstanding (Diluted)	11	10	10	9
Shares Change (YoY)	2.97%	1.42%	11.86%	-
EPS (Basic)	-0.26	-0.17	-0.10	-0.23
EPS (Diluted)	-0.26	-0.17	-0.10	-0.23
EBITDA	-1.83	-1.55	-0.41	-1.85
D&A For EBITDA	0.16	0.16	0.16	0.1
EBIT	-1.99	-1.71	-0.57	-1.94

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q